GO
| HSI1 | 26,388.44 | +40.53 | 277.77B |
| HSCEI1 | 8,876.38 | -5.99 | 91.33B |
| Back Zoom + Zoom - Block Traded | |
|
2026-05-13 16:01:53 TIGERMED (03347.HK) disclosed that its co-founders and controlling shareholders, Ye Xiaoping and Cao Xiaochun, received formal case filing notices from the China Securities Regulatory Commission for failing to promptly disclose equity changes after their shareholding ratios fell by more than 10 ppts between December 2014 and May 2026, Citi said in a research report. Citi believed this constitutes a compliance procedural violation, with the most likely resolution being a warning and fine, pending clarification of penalties. The broker believed the incident has no impact on the company's fundamentals and viewed any share price weakness as an enhanced buying opportunity. The broker assigned TIGERMED CONSULTING (300347.SZ) an A-share TP of RMB67 and maintained a Buy rating. ~ AASTOCKS Financial News Website: www.aastocks.com | |